8-K: Ludwig Enterprises Announces Corporate Rebrand and Launch of Revealia Cancer Screening Test

Ludwig Enterprises, Inc. is rebranding to Revealia, Inc. and plans to launch its cancer screening test, Revealia, in 2024.

Summary

• Ludwig Enterprises, Inc. is changing its name to Revealia, Inc. to align with its cancer screening product, also named Revealia.
• The company plans to launch the Revealia cancer screening test in the direct-to-consumer market in 2024.
• Revealia is a non-invasive cheek swab test that uses mRNA-based genetic signals and machine learning AI technology.
• The company has collected over 3000 samples and continues to gather data from medical clinics across the US.
• Ludwig intends to apply to trade on the OTCQB market as a step towards a higher listing like NASDAQ or CBOE.

Sentiment

Score: 7

Explanation: The document is positive due to the upcoming product launch and corporate rebranding, but it also acknowledges risks and uncertainties.

Positives

• The launch of Revealia is a significant step for the company.
• The non-invasive nature of the cheek swab test makes it convenient for consumers.
• The use of mRNA-based genetic signals and AI technology positions the company as innovative.
• The company's plan to move to the OTCQB market is a positive step for growth.
• The company has collected a substantial number of samples, indicating progress in development.

Risks

• The company's forward-looking statements are subject to risks and uncertainties.
• The company's ability to procure, price, retain, and complete projects could impact results.
• Changes in products and competition could affect the company's performance.
• The timing of FINRA approval for the name change is uncertain.

Future Outlook

The company plans to launch the Revealia cancer screening test in 2024 and seek a higher exchange listing, such as NASDAQ or CBOE, after moving to the OTCQB market.

Management Comments

• Ludwig has uncovered potentially game-changing mRNA-based genetic signals associated with the presence of cancer, stated Marvin S. Hausman, MD, CEO.

Industry Context

The announcement places Ludwig Enterprises in the competitive genetic cancer screening market, aiming to compete with companies like Exact Sciences, which launched Cologuard. The direct-to-consumer approach is a growing trend in the healthcare industry.

Comparison to Industry Standards

• Exact Sciences' Cologuard, launched in 2014, is a benchmark in the colorectal cancer screening market, and Revealia aims to compete in this space.
• The use of mRNA-based genetic signals and AI technology positions Revealia as a potentially more advanced screening method compared to traditional tests.
• The direct-to-consumer model is similar to other companies in the genetic testing space, but the non-invasive cheek swab approach may offer a competitive advantage.

Stakeholder Impact

• Shareholders will be impacted by the corporate name change and potential increase in stock value.
• Customers will benefit from the availability of a convenient cancer screening test.
• Employees will be impacted by the company's growth and expansion.

Next Steps

• The company will seek FINRA approval for the corporate name change.
• The company will apply to trade on the OTCQB market.
• The company will launch the Revealia cancer screening test in 2024.

Key Dates

Keywords

cancer screening, mRNA genomics, machine learning AI, biotechnology, Revealia, Ludwig Enterprises, OTCQB, genetic testing, healthcare